1Furuta T, Shirai N, Takashima M, et al. Effect of Genotypic Differences in CYP2C19 on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Proton Pump Inhibitor, Amoxicillin, and Clarithromycin Clin Pharmacol Ther 2001;69:158–682 2Editor: David Johnson, M.D., F.A.C.G.. Get access to over 12 million other articles!" />
TITLE

PPIs meet the liver1 1Furuta T, Shirai N, Takashima M, et al. Effect of Genotypic Differences in CYP2C19 on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Proton Pump Inhibitor, Amoxicillin, and Clarithromycin Clin Pharmacol Ther 2001;69:158–682 2Editor: David Johnson, M.D., F.A.C.G.

AUTHOR(S)
Souney, Paul F.
PUB. DATE
March 2002
SOURCE
American Journal of Gastroenterology;Mar2002, Vol. 97 Issue 3, p756
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
This prospective trial evaluated whether CYP2C19 genotype status was related to eradication rates of Helicobacter pylori using triple therapy with a proton pump inhibitor, clarithromycin, and amoxicillin with an attempt to establish a strategy for treating patients whose H. pylori was not eradicated. Study patients consisted of men and women with endoscopically proven gastric ulcers or duodenal ulcers or long-standing gastritis who were positive for H. pylori using a rapid urease test, culture, and histology. The drug regimen for eradication of H. pylori included 20 mg of omeprazole or 30 mg of lansoprazole b.i.d. (randomly selected for proton pump inhibitor use), 200 mg of clarithromycin t.i.d., and 500 mg of amoxicillin t.i.d. for 1 wk. Patients with gastric or duodenal ulcer were treated with a daily dose of 20 mg of omeprazole or 30 mg of lansoprazole for 5–7 wk after triple therapy. Patients whose H. pylori was not eradicated with the initial regimen were retreated with 30 mg of lansoprazole q.i.d. and amoxicillin q.i.d. for 2 wk. Patients received endoscopic evaluation and confirmation of H. pylori status before treatment and 1 month after the end of all treatments. Endoscopic biopsy samples were obtained for rapid urease testing, bacteriological culture for antimicrobial sensitivity, and polymerase chain reaction analysis for genotyping of CYP2C19 status of patients. Patients were categorized into three groups based upon CYP2C19 genotype: homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers.There were no significant differences between the groups in demographic or disease state measures. Overall, 226 of 261 patients (86.6%) achieved cure of H. pylori infection. Thirty-three of 261 patients were infected with clarithromycin-resistant strains, whereas culture results revealed no amoxicillin-resistant strains. Differences in the status of CYP2C19 genotype and clarithromycin-resistant H. pylori were significantly associated with success or failure of H. pylori eradication. Eradication rates were 72.7% for homozygous extensive metabolizers, 92.1% for heterozygous metabolizers, and 97.8% for poor metabolizers. Thirty-four of 35 patients who did not achieve H. pylori eradication were classified as extensive metabolizers. Thirty-two of these patients were retreated, achieving H. pylori eradication.
ACCESSION #
7770832

 

Related Articles

  • Cochrane for Clinicians. YANCEY, JOSEPH; NEAMAND-CHENEY, KARI // American Family Physician;12/1/2014, Vol. 90 Issue 11, preceding p767 

    The article discusses research done on the treatment of Helicobacter pylori infection. It references the study "Optimum Duration of Regimens for Helicobacter pylori Eradication" by Y. Yuan and colleagues, published in the 2013 issue of "Cochrane Database of Systematic Reviews." Topics discussed...

  • Omeprazole was effective in the short term for uninvestigated dyspepsia. Rabeneck, L.; Souchek, J.; Wristers, k.; Talley, Nicholas J. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p70 

    Summarizes a study that determined whether a proton-pump inhibitor is effective in the treatment of patients with uninvestigated dyspepsia. Characterization of the patients; Main outcome measures; Results of the study.

  • Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Proton Pump Inhibitors. Dam, Claus; Bygum, Anette // Acta Dermato-Venereologica;2008, Vol. 88 Issue 1, p87 

    A letter to the editor is presented concerning the treatment of subacute cutaneous lupus erythematosus using proton pump inhibitors.

  • PPIs and clopidogrel.  // Critical Care Alert;May2009 Pharmacology Watch, p2 

    The article focuses on the efficiency of proton pump inhibitors (PPIs) in reducing the effect of clopidogrel on platelet aggregate.

  • Pantoprazole intravenous. My-Trang Le; Cano, Steven // Drug Utilization Review;Nov2001, Vol. 17 Issue 11, p1 

    Presents information on pantoprazole, an intravenous form of the benzimidazole proton pump inhibitor class drug. Pharmacokinetics; Pharmacodynamics; Dosage and administration.

  • Biological Plausibility Between Proton Pump Inhibitory Therapy and Hip Fracture: Hypermocysteinemia Can Be the Link. Roblin, Xavier; Phelip, Jean Marc // American Journal of Gastroenterology (Springer Nature);Apr2009, Vol. 104 Issue 4, p1052 

    A letter to the editor is presented in response to the article regarding the biological validity of proton pump inhibitory therapy (PPI) and hip fracture in the previous issue.

  • It Is Difficult to Discontinue PPI Treatment in Patients With GERD. Bjornsson, Einar // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p367 

    A letter to the editor is presented in response to an article regarding the development of dyspepsia in healthy volunteers after stopping proton-pump inhibitors (PPI) therapy.

  • Omeprazole.  // Reactions Weekly;8/21/2010, Issue 1315, p37 

    The article describes the case of a 52-year-old woman who took omeprazile for acid reflux and developed burning mouth syndrome-like symptoms.

  • Omeprazole/pantoprazole.  // Reactions Weekly;8/21/2010, Issue 1315, p37 

    The article describes the case of a 60-year-old man who had neutropenia initially while taking omeprazole and later during treatment with pantoprazole.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics